33 results about "Hypertriglyceridemia" patented technology

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and / or an adjuvant.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

The present invention relates to pharmaceutical composition(s) comprising particles comprising one or more compounds which are inhibitors of microsomal triglyceride transfer protein and / or apolipoprotein B (Apo B) secretion, wherein at least 50% of the particles are characterized by a volume particle fraction less than 10 μm, more preferably less than 5 μm, more preferably less than 2.5 μm. The pharmaceutical composition can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

This invention discloses a method for establishing an improved mouse model of postprandial hypertriglyceridemia, belonging to the field of model construction technology. The key technical points are as follows: the method includes the following steps: obtaining a predetermined number of mouse models, which are then divided into a control group and a model group; administering gavage to both the model group and the control group for 120 minutes; sampling the mice in the model group and the control group after step S2, obtaining samples from both groups; and detecting glucose and lipid-related biochemical indicators, serum SOD, and MDA levels in the samples from both groups. In this invention, a mouse model of hypertriglyceridemia simulating the postprandial dietary state in humans is established through a combination of glucose and lipid administration via gavage. This will provide a research foundation for traditional Chinese medicine research on postprandial hypertriglyceridemia and related glucose and lipid metabolic diseases, and can also provide a model reference for the evaluation of lipid-lowering and hypoglycemic drugs and the development of health products.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

Prenylated tetrahydroquinolines and quinolines and pharmaceutical compositions comprising the same. Prenylated tetrahydroquinoline and quinolines and pharmaceutical compositions comprising the same, for use in the prevention and / or treatment of peroxisome proliferator-activated receptor (PPAR)-mediated diseases such as metabolic syndrome, type 2 diabetes mellitus, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, dyslipidemic atherosclerosis, metabolic dysfunction- associated fatty liver disease (MAFLD), cardiovascular disease, cardiometabolic disease, neurodegenerative disease, Friedreich's ataxia, Parkinson's disease, multiple sclerosis, Alzheimer's disease, autoimmune disease, rheumatoid arthritis, autoimmune thyroid disease, dermatological disease, and cancer.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and / or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.

The invention relates to a home management method and system for a patient with hypertriglyceridemia acute pancreatitis, and belongs to the technical field of data analysis. The method comprises the following steps: acquiring auxiliary analysis data of the patient; forming multi-modal sequence data in a time dimension based on the auxiliary analysis data; encoding the multi-modal sequence data based on a time sequence Transform of an attention mechanism, and generating a multi-modal feature vector; inputting the multi-modal feature vector into a risk prediction model, and outputting a deterioration risk probability of the patient; and outputting the health guidance of the patient based on the multi-modal feature vector. The multi-modal data is captured through an attention mechanism, the risk probability is quantified according to the multi-modal data, the potential deterioration risk can be perceived in the early stage, the recurrence and illness worsening risks are remarkably reduced, the health guidance is generated based on the individualized features of the patient, the health guidance is more suitable for the actual life of the patient, and the patient experience is improved. And the management participation and compliance of the patient are further improved.

The invention provides a double-layer tablet containing ezetimibe and fenofibrate. The double-layer tablet comprises an ezetimibe quick release layer and a fenofibrate slow release layer, the ezetimibe quick-release layer comprises ezetimibe, a quick-release layer filler, a quick-release layer surfactant, a quick-release layer adhesive, a quick-release layer disintegrating agent and a quick-release layer lubricant; the fenofibrate sustained-release layer comprises fenofibrate, a sustained-release layer filler, a sustained-release layer disintegrating agent, a sustained-release layer adhesive, a sustained-release layer solubilizer, a sustained-release layer sustained-release framework material and a sustained-release layer lubricant. The invention also provides a preparation method of the double-layer tablet. The double-layer tablet provided by the invention can be used for clinical treatment of hypercholesterolemia, hypertriglyceridemia and mixed dyslipidemia, the levels of triglyceride, total cholesterol and LDL-C are comprehensively reduced, the level of HDL-C is increased, and the occurrence rate of adverse reactions is relatively low.

The invention discloses a traditional Chinese medicine composition for treating mild and moderate hypertriglyceridemia, and belongs to the technical field of prevention and treatment of hypertriglyceridemia. The traditional Chinese medicine composition consists of the following components in parts by weight: 6-15 parts of broadleaf holly leaf, 3-10 parts of rhizoma acori graminei, 3-10 parts of turmeric, 6-15 parts of hawthorn and 3-10 parts of lotus leaf. The traditional Chinese medicine composition can effectively reduce the high triglyceride level of serum of a patient, helps the serum to recover to a normal value, also has a very good regulation and control effect on other blood fat indexes, can also improve intestinal flora ecology, alleviate the fatty liver degree of the patient, and helps the patient to recover to a health level in multiple dimensions. The traditional Chinese medicine composition has a very good treatment effect on light and medium hypertriglyceridemia patients who do not reach the western medicine medication standard, is simple in components, is prepared from medicinal and edible materials, has no side effect, and is suitable for long-term administration.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit mitochondrial amidoxime reducing component 1 (MARC1) gene expression. Also disclosed are pharmaceutical compositions that include MARC1 RNAi agents and methods of use thereof. The MARC1 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the MARC1 RNAi agents in vivo provides for inhibition of MARC1 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by MARC1 gene expression, including nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1-related disease.

The present disclosure relates to methods of treating, preventing, or managing a cardiovascular and / or metabolic disorder in a human subject in need thereof by administering a human FGF21 protein variant, wherein the metabolic and / or cardiovascular disorder is selected from hypercholesterolemia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity.

This invention belongs to the field of biomedical technology, specifically relating to an isoflavone compound, its preparation method, and its application. This compound is derived from *Rotenoporosis capillaris* (a type of vine). Derris eriocarpa The stem of *Derris fusiforme* was analyzed using 1D and 2D nuclear magnetic resonance (NMR) spectra (1H NMR, 1C NMR, and high-resolution mass spectrometry), and its structural formula is shown below: Chemical name: 5-hydroxy-6-(2"-hydroxy-3"-methylbut-3"-enyl)-3-(4'-hydroxyphenyl)-7-methoxyisoflavone. Screening using the Sci-finder database revealed that this compound is a novel isoflavone, isolated for the first time from *Derris fusiforme*. Lipid-lowering activity experiments showed that at the same drug concentration (25 μg / mL) as the positive control, it significantly reduced intracellular total cholesterol and triglyceride levels. p <0.001). Therefore, this novel isoflavone compound can be used to prepare drugs, health products, functional foods, or special medical foods for the prevention or treatment of hypertriglyceridemia, hyperlipidemia, obesity, or metabolic syndrome.

The application discloses an aptamer for specifically distinguishing different glycosylation forms of ApoC-III, and a screening method and application thereof. The aptamer is specifically combined with non-glycosylated ApoC-III0, ApoC-III1, ApoC-III2, ApoC-III3 and total ApoC-III, and the nucleic acid sequence of the aptamer comprises any one or a combination of at least two of sequences shown in SEQ ID NO:1-SEQ ID NO:5. The aptamer has high affinity and strong specificity, can accurately distinguish the glycosylation spectrum of ApoC-III, and can be used for preparing a high-precision diagnostic kit for hypertriglyceridemia, atherosclerotic cardiovascular diseases and the like.

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.

The present invention relates to an RNAi composition for inhibiting the expression of apolipoprotein C-III, and the use thereof. The RNAi composition can be used for treating and / or preventing APOC3-associated diseases or conditions such as cardiovascular diseases, hypertriglyceridemia and pancreatitis.

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

The present application provides a compound shown in formula I, wherein R1, R2, R3 are defined in the specification. The compound shown in formula I of the present application can effectively inhibit MOGAT2 enzyme activity, and has a clinical application prospect for treating and / or preventing obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, high VLDL, high fatty acid, diabetes or arteriosclerosis.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

The present invention relates to pharmaceutical composition(s) comprising particles comprising one or more compounds which are inhibitors of microsomal triglyceride transfer protein and / or apolipoprotein B (Apo B) secretion, wherein at least 50% of the particles are characterized by a volume particle fraction less than 10 μm, more preferably less than 5 μm, more preferably less than 2.5 μm. The pharmaceutical composition can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

The present disclosure relates to methods of using GLP-1 analogs and compositions thereof to treat metabolic disorders, such as obesity, diabetes, fatty liver disease associated with metabolic dysfunction (MASLD), steatohepatitis associated with metabolic dysfunction (MASH), and hypertriglyceridemia. More specifically, the present disclosure relates to a method for treating obesity in a subject comprising administering to the subject a therapeutically effective amount of GL0034. The disclosure also relates to a method for treating a metabolic disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of GL0034. The disclosure further relates to compositions comprising GL0034 for use in the treatment of obesity, diabetes, or other metabolic disorders in a subject.

25HC3S choline and crystalline 25HC3S choline are described herein.Further disclosed herein is the pharmaceutical preparation of 25HC3S choline, for example, using crystalline 25HC3S choline, and the method of using it to treat or prevent diseases, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic condition, autoimmune condition, inflammatory condition, neurological condition, Epstein-Barr virus-related proliferation and the condition related to fat accumulation and inflammation.Also provided is the method of preparing 25HC3S, including crystalline 25HC3S choline.

This disclosure relates to methods for using GLP-1 analogs and compositions thereof for the treatment of metabolic disorders such as obesity, diabetes mellitus, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), and hypertriglyceridemia. More specifically, this disclosure relates to a method for treating obesity in a subject, comprising administering a therapeutically effective dose of GL0034 to the subject. This disclosure also relates to a method for treating a metabolic disorder in a subject requiring it, comprising administering a therapeutically effective dose of GL0034 to the subject. This disclosure further relates to compositions comprising GL0034 for the treatment of obesity, diabetes mellitus, or other metabolic disorders in a subject.

To provide modulators of C3 expression for treating apolipoprotein APOC3 associated disorders, such as hypertriglyceridemia.SOLUTION: To provide apolipoprotein C3 (APOC3) gene-targeting double-stranded RNA (dsRNA) agents. Also provided are methods of inhibiting APOC3 gene expression and methods of preventing and treating APOC3 associated disorders, such as hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic diabetic hepatitis, polycystic ovarian syndrome, kidney disease, obesity-type 2 fat (insulin-resistance), high-blood pressure, atherosclerosis, and pancrease using such dsRNA agents.SELECTED DRAWING: None